Skip to main content
Guttmacher Institute

Search

  • X
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
  • Contact

Highlights

  • Roe v. Wade Overturned
  • Reproductive Health Impact Study
  • Adding It Up
  • Abortion Worldwide
  • Guttmacher-Lancet Commission
  • Monthly Abortion Provision Study
  • US policy resources
  • State policy resources
  • State legislation tracker

Reports

  • Global
  • United States

Articles

  • Global research
  • US research
  • Policy analysis
  • Guttmacher Policy Review
  • Opinion

Fact Sheets

  • Global
  • United States
  • US State Laws and Policies

Data, Videos & Visualizations

  • Data center
  • Videos
  • Infographics
  • Public-use data sets

Peer-reviewed Journals

  • International Perspectives on Sexual and Reproductive Health (1975–2020)
  • Perspectives on Sexual and Reproductive Health (1969–2020)

Global

  • Abortion
  • Contraception
  • HIV & STIs
  • Pregnancy
  • Teens

US

  • Abortion
  • Contraception
  • HIV & STIs
  • Pregnancy
  • Teens

Our Work by Geography

  • Global
  • Africa
  • Asia
  • Europe
  • Latin America & the Caribbean
  • Northern America
  • Oceania

Who We Are

  • About
  • Staff
  • Board
  • Job opportunities
  • Newsletter
  • History
  • Contact
  • Conflict of Interest Policy

Media

  • Media office
  • News releases

Support Our Work

  • Make a gift today
  • Monthly Giving Circle
  • Ways to Give
  • Guttmacher Guardians
  • Guttmacher Legacy Circle
  • Financials
  • 2024 Impact Report

Awards & Scholarships

  • Darroch Award
  • Richards Scholarship
  • Bixby Fellowship
Donate
Guttmacher Institute
Donate

Highlights

  • Roe v. Wade Overturned
  • Reproductive Health Impact Study
  • Adding It Up
  • Abortion Worldwide
  • Guttmacher-Lancet Commission
  • Monthly Abortion Provision Study
  • US policy resources
  • State policy resources
  • State legislation tracker

Reports

  • Global
  • United States

Articles

  • Global research
  • US research
  • Policy analysis
  • Guttmacher Policy Review
  • Opinion

Fact Sheets

  • Global
  • United States
  • US State Laws and Policies

Data, Videos & Visualizations

  • Data center
  • Videos
  • Infographics
  • Public-use data sets

Peer-reviewed Journals

  • International Perspectives on Sexual and Reproductive Health (1975–2020)
  • Perspectives on Sexual and Reproductive Health (1969–2020)

Global

  • Abortion
  • Contraception
  • HIV & STIs
  • Pregnancy
  • Teens

US

  • Abortion
  • Contraception
  • HIV & STIs
  • Pregnancy
  • Teens

Our Work by Geography

  • Global
  • Africa
  • Asia
  • Europe
  • Latin America & the Caribbean
  • Northern America
  • Oceania

Who We Are

  • About
  • Staff
  • Board
  • Job opportunities
  • Newsletter
  • History
  • Contact
  • Conflict of Interest Policy

Media

  • Media office
  • News releases

Support Our Work

  • Make a gift today
  • Monthly Giving Circle
  • Ways to Give
  • Guttmacher Guardians
  • Guttmacher Legacy Circle
  • Financials
  • 2024 Impact Report

Awards & Scholarships

  • Darroch Award
  • Richards Scholarship
  • Bixby Fellowship
Donate
  • X
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
  • Contact
Policy Analysis
May 2023

Guttmacher Expert Testimony in Support of Approving Over-the-Counter Status for Opill Without an Age Restriction

Authors

Megan L. Kavanaugh, Guttmacher Institute

Reproductive rights are under attack. Will you help us fight back with facts?

Donate

Oral testimony at the Food and Drug Administration’s Open Public Hearing to discuss Opill (sNDA 017031/S-041)​ by Megan Kavanaugh, DrPH​, Principal Research Scientist, Guttmacher Institute​ 

Hello. My name is Megan Kavanaugh, and I am a Principal Research Scientist at the Guttmacher Institute, an independent, not-for-profit organization focusing on reproductive health research and policy analysis in the United States and globally.  

I have no financial disclosures to make. 

I and my colleagues have conducted extensive research examining contraception in the United States, and evidence generated by us and many other researchers supports the safety of contraception and its centrality in ensuring people of all ages can achieve reproductive health, autonomy and dignity. 

Today, I want to make five important points about the body of evidence from the behavioral health field that supports a switch to over-the-counter status for OPill that is inclusive of all ages.  

One, young people may have the most to gain from over-the-counter access to contraception. Adolescents experience unique barriers to accessing contraception within the health care system, including confidentiality concerns and increased stigma, which would be minimized with broader, over-the-counter access to contraception. 

Two, despite these barriers, most adolescents use contraceptives at both first sex and most recent sex. The most recent available data indicate that 77% of females and 91% of males aged 15–19 reported contraceptive use the first time they had sexual intercourse, and 91% of females and 94% of males reported that they or their partner had used contraception the last time they had sexual intercourse.  

Three, the science is clear that recent declines in US adolescent pregnancies that occurred too early or were unwanted can be attributed primarily to increases in adolescent contraceptive use. 

Four, levels of sexual activity among adolescents under age 13 are low and have been declining over time. About 4% of adolescents aged 13 and under reported being sexually active in 2015, down from 5.6% in 2013.  

Five, there is significant evidence from dozens of well-conducted studies that increased availability of contraception does not increase sexual activity among young people. Further, between 2007 and 2014, more adolescents were using contraceptives, they were using more effective methods and they were using them more consistently—all while adolescent sexual activity rates remained unchanged. 

In short, robust scientific evidence very much supports that over-the-counter access for OPill would have significant benefits for public health and individuals' well-being and should be inclusive of people of all ages. Any age restriction would be counterproductive, as adolescents face both greater chances of unwanted pregnancy, as well as potentially greater ramifications of those pregnancies, than adults. I urge the FDA to consider the most current and accurate data available in making an evidence-based decision on making Opill available over the counter without an age restriction; the science overwhelmingly supports a vote of “yes.” 

Thank you again for the opportunity to speak today. 

First published online: May 9, 2023

Share

Printer-friendly version

Read More

Policy Analysis

Promiscuity Propaganda: Access to Information and Services Does Not Lead to Increases in Sexual Activity

Guttmacher Policy Review
Policy Analysis

Over-the-Counter Oral Contraceptives: Getting the Details Right

Policy Analysis

Why Family Planning Policy and Practice Must Guarantee a True Choice of Contraceptive Methods

Guttmacher Policy Review

Topic

United States

  • Contraception
  • Teens

Geography

  • Northern America: United States

US Policy Resources

More
Guttmacher Institute

Center facts. Shape policy.
Advance sexual and reproductive rights.

Donate Now
Newsletter Signup  Contact Us 
  • X
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
  • Contact

Footer

  • Privacy Policy
  • Accessibility Statement
© 2025 Guttmacher Institute. The Guttmacher Institute is registered as a 501(c)(3) nonprofit organization under the tax identification number 13-2890727. Contributions are tax deductible to the fullest extent allowable.